

# Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 24:00 local time 21 March 2021

Situation Report No. 248 - Kingdom of Bahrain  
22<sup>th</sup> of March, 2021



	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
<b>Total</b>	122,524,424	2,703,620	7,123,963	153,419
<b>New</b>	2,113,529 in 4 days	38,599 in 4 days	151,038 in 4 days	1,858 in 4 days


## Kingdom of Bahrain

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests	Vaccine First Dose	Vaccine Second Dose
	<b>Total</b>	135,982	128,434	500	7,048	57	3,414,888	417,364
<b>New</b>	2,845 in 4 days	2,354 in 4 days	11 in 4 days	-	-	62,287 in 4 days	-	-


## HIGHLIGHTS

- The Mortality were: 10 Bahraini citizens (5 male (42, 62, 70, 72 and 92 years old) and 5 female (40, 59, 65, 66 and 67 years old) and 36 years old male expatriates.
- Increasing number of citizens and residents continue to take COVID-19 Vaccine in Bahrain; and Ministry of Health (MOH) revealed the total number of individuals vaccinated as of 21 March 2021 for the first dose (417,364) and for the second dose (235,872).
- MOH urged the elderly, pregnant or breastfeeding women, and those with underlying medical conditions to register for vaccination to safeguard their health and the community
- Latest figures revealed that over 61,000 public face mask violations were fined.
- The World Health Organization (WHO) pressed the world to keep administering AstraZeneca's Covid-19 shots, adding endorsement to the European and British Regulators after allegations of blood clotting.
- National Medical Taskforce for Combating the Coronavirus announced that from Sunday 21st March, Sitra Mall will be transformed into a large COVID-19 vaccination center for accommodating increases in vaccination registrations.
- Visually-impaired students in Bahrain are offered e-learning opportunities during the COVID-19 pandemic.
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies; see link below.
- WHO: Guidance on informing vaccination programs: a guide to the design and conduct of dengue sero-surveys; see link below.
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic; see link below.
- WHO: Emergency Global Supply Chain System(COVID-19) catalogue; see link below.
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immuno assay; see link below.
- WHO: Global TB progress a trisk; see link below.
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination; see link below.
- WHO: Interim guidance Operational considerations for COVID-19 surveillance using GISRS; see link below.
- WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic; see link below.
- WHO: As COVID-19 spread accelerates, JHR Emergency Committee urges focus on measures that work; see link below.
- WHO: The push for sCOVID-19 vaccines; see link below.
- WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines; see link below.
- WHO Living Guideline: The rapicuts and COVID-19; see link below.
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19; see link below.
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector; see link below.
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response; see link below.
- WHO: COVID-19 vaccine introduction and deployment costing tool; see link below.
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19; see link below.
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19; see link below.
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021; see link below.
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages; see link below.
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access; see link below.
- WHO: Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZeneca; see link below.
- WHO: Rotavirus vaccines made available for use in humanitarian crises; see link below.
- WHO: COVID-19 Virtual Press Conference transcript; see link below.
- WHO: Draft landscape and tracker of COVID-19 candidate vaccines; see link below.
- WHO: Access to COVID-19 tools funding commitment tracker; see link below.
- WHO: New research highlights risks of separating newborns from mothers during COVID-19 pandemic; see link below.
- WHO Guideline Development Group Living Guidelines for COVID-19; see link below.
- WHO: Weekly operational update on COVID-19 - 16 March 2021; see link below.
- WHO statement on AstraZeneca COVID-19 vaccine safety signals; see link below.


Number of New Cases



Total Number of Cases



Number of New Deaths



## IMPORTANT LINKS

- Daily COVID-19 updates on MOH website: <https://www.moh.gov.bh/>
- WHO's COVID-19 weekly situation reports: [https://www.who.int/docs/default-source/coronavirus/situation-reports/20200317-weekly-epi-update-1.pdf?sfvrsn=6d44976\\_4](https://www.who.int/docs/default-source/coronavirus/situation-reports/20200317-weekly-epi-update-1.pdf?sfvrsn=6d44976_4)
- WHO's COVID-19 dashboard: <https://covid19.who.int/>
- WHO: New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies: <https://www.who.int/news-room/detail/19-03-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies>
- WHO: Guidance on informing vaccination programs: a guide to the design and conduct of dengue sero-surveys: <https://www.who.int/publications/item/978-92-4-122258-9>
- WHO: Responding to non-communicable diseases during and beyond the COVID-19 pandemic: <https://bit.ly/32v5dtr>
- WHO: Emergency Global Supply Chain System(COVID-19) catalogue: <https://www.who.int/publications/item/emergency-global-supply-chain-system-covid-19-catalogue>
- WHO: Interim guidance on Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immuno assays 202101VF: <https://bit.ly/37d451h>
- WHO: Global TB progress a trisk: <https://bit.ly/37d451h>
- WHO: SAGE values framework for the allocation and prioritization of COVID-19 vaccination: <https://bit.ly/320wvWQ>
- WHO: Interim guidance Operational considerations for COVID-19 surveillance using GISRS: <https://bit.ly/34AP9EG>
- WHO: Statement by WHO Director of Programme Management on COVID-19 pandemic: <https://bit.ly/3772016>
- WHO: As COVID-19 spread accelerates, JHR Emergency Committee urges focus on measures that work: <https://bit.ly/3772016>
- WHO: The push for sCOVID-19 vaccines: <https://bit.ly/3772016>
- WHO-ICMRA joint statement on the need for improved global regulatory alignment on COVID-19 medicines and vaccines: <https://bit.ly/3pan5M>
- WHO Living Guideline: The rapicuts and COVID-19: <https://www.who.int/publications/item/therapeutics-and-covid-19-living-guideline>
- WHO: Interim guidance on Diagnostics, therapeutics, vaccine readiness, and other health products for COVID-19: [https://www.who.int/publications/item/WHO-2019-nCoV-HCF\\_assessment-Products-2020.1](https://www.who.int/publications/item/WHO-2019-nCoV-HCF_assessment-Products-2020.1)
- WHO: Evidence to recommendations: COVID-19 mitigation in the aviation sector: <https://www.who.int/publications/item/evidence-to-recommendation-covid-19-mitigation-in-the-aviation-sector>
- WHO: Health workforce policy and management in the context of the COVID-19 pandemic response: [https://icd.who.int/collections/Download/WHO-2019-nCoV\\_health\\_workforce\\_2020.1.pdf](https://icd.who.int/collections/Download/WHO-2019-nCoV_health_workforce_2020.1.pdf)
- COVID-19 vaccine introduction and deployment costing tool: <https://www.who.int/publications/item/1206633753>
- WHO: Considerations for implementing a risk-based approach to international travel in the context of COVID-19: [https://www.who.int/publications/item/WHO-2019-nCoV\\_risk-based-international-travel-2020.1](https://www.who.int/publications/item/WHO-2019-nCoV_risk-based-international-travel-2020.1)
- WHO: Risk assessment tool to inform mitigation measures for international travel in the context of COVID-19: [https://www.who.int/publications/item/WHO-2019-nCoV\\_risk-assessment\\_tool-2020.1](https://www.who.int/publications/item/WHO-2019-nCoV_risk-assessment_tool-2020.1)
- WHO: COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021: <https://www.who.int/news/19-03-2020-covax-announces-additional-deals-to-access-promising-covid-19-vaccine-candidates-plans-global-rollout-starting-q1-2021>
- WHO: Rational use of personal protective equipment for coronavirus disease (COVID-19) and considerations during severe shortages: <https://www.who.int/publications/item/rational-use-of-personal-protective-equipment-for-coronavirus-disease-covid-19-and-considerations-during-severe-shortages>
- WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access: <https://www.who.int/news/19-03-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access>
- Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZeneca: <https://www.who.int/publications/item/background-document-on-the-azd1222-vaccine-against-covid-19-developed-by-oxford-university-and-astrazeneca>
- WHO: Rotavirus vaccines made available for use in humanitarian crises: <https://www.who.int/news/19-03-2021-rotavirus-vaccines-made-available-for-use-in-humanitarian-crises>
- WHO: COVID-19 Virtual Press Conference transcript: <https://www.who.int/publications/item/covid-19-virtual-press-conference-transcript--8-march-2021>
- WHO: Draft landscape and tracker of COVID-19 candidate vaccines: <https://www.who.int/publications/item/draft-landscape-of-covid-19-candidate-vaccines>
- WHO: Access to COVID-19 tools funding commitment tracker: <https://www.who.int/publications/item/access-to-covid-19-tools-tracker>
- WHO: New research highlights risks of separating newborns from mothers during COVID-19 pandemic: <https://www.who.int/news/item/16-03-2021-new-research-highlights-risks-of-separating-newborns-from-mothers-during-covid-19-pandemic>
- WHO Guideline Development Group Living Guidelines for COVID-19: <https://www.who.int/publications/item/who-guideline-development-group-living-guidelines-for-covid-19-biographies>
- WHO: Weekly operational update on COVID-19 - 16 March 2021: <https://www.who.int/publications/item/weekly-operational-update-on-covid-19--16-march-2021>
- WHO statement on AstraZeneca COVID-19 vaccine safety signals: <https://www.who.int/news/item/17-03-2021-who-statement-on-astrazeneca-covid-19-vaccine-safety-signals>

## IMPORTANT CONTACTS

- The National Focal Person is Dr. Najat Mohamed Abulfateh, email: [NAIi@health.gov.bh](mailto:NAIi@health.gov.bh)
- International Health Regulations focal person is Dr. Kubra Salman, email: [knasser@health.gov.bh](mailto:knasser@health.gov.bh)